Sorafenib, a targeted therapy for inoperable or advanced hepatocellular carcinoma (HCC) and clear cell renal cell carcinoma (ccRCC), is known to be a substrate for both OATP1B1 and OATP1B3. Here, SLCO1B3 is linked to hepatocellular carcinoma.